Validation of the Role of Thrombin Generation Potential by a Fully Automated System in the Identification of Breast Cancer Patients at High Risk of Disease Recurrence
Patricia Gomez-Rosas,
Marina Pesenti,
Cristina Verzeroli,
Cinzia Giaccherini,
Laura Russo,
Roberta Sarmiento,
Giovanna Masci,
Luigi Celio,
Mauro Minelli,
Sara Gamba,
Carmen Julia Tartari,
Carlo Tondini,
Francesco Giuliani,
Fausto Petrelli,
Andrea D'Alessio,
Giampietro Gasparini,
Roberto Labianca,
Armando Santoro,
Filippo De Braud,
Marina Marchetti,
Anna Falanga
Affiliations
Patricia Gomez-Rosas
Immunohematology and Transfusion Medicine, Hospital Papa Giovanni XXIII, Bergamo, Italy
Marina Pesenti
Immunohematology and Transfusion Medicine, Hospital Papa Giovanni XXIII, Bergamo, Italy
Cristina Verzeroli
Immunohematology and Transfusion Medicine, Hospital Papa Giovanni XXIII, Bergamo, Italy
Cinzia Giaccherini
Immunohematology and Transfusion Medicine, Hospital Papa Giovanni XXIII, Bergamo, Italy
Laura Russo
Immunohematology and Transfusion Medicine, Hospital Papa Giovanni XXIII, Bergamo, Italy
Roberta Sarmiento
Oncology Unit, Hospitals San Filippo Neri and San Giovanni Addolorata, Rome, Italy
Giovanna Masci
Medical Oncology and Hematology, IRCCS Humanitas Institute, Rozzano, Italy
Luigi Celio
Medical Oncology and Hematology, IRCCS National Cancer Institute, Milan, Italy
Mauro Minelli
Oncology Unit, Hospitals San Filippo Neri and San Giovanni Addolorata, Rome, Italy
Sara Gamba
Immunohematology and Transfusion Medicine, Hospital Papa Giovanni XXIII, Bergamo, Italy
Carmen Julia Tartari
Immunohematology and Transfusion Medicine, Hospital Papa Giovanni XXIII, Bergamo, Italy
Carlo Tondini
Oncology Unit, Hospital Papa Giovanni XXIII, Bergamo, Italy
Francesco Giuliani
Medical Oncology Unit, IRCCS Istituto Tumori Giovanni Paolo II, Bari, Italy
Fausto Petrelli
Oncology Unit, Hospital Treviglio-Caravaggio, Treviglio, Italy
Andrea D'Alessio
Department of Medicine, Gruppo San Donato, Policlinico San Marco, Bergamo, Italy
Giampietro Gasparini
Oncology Unit, Hospitals San Filippo Neri and San Giovanni Addolorata, Rome, Italy
Roberto Labianca
Department of Oncology Bergamo Province, Hospital Papa Giovanni XXIII, Bergamo, Italy
Armando Santoro
Medical Oncology and Hematology, IRCCS Humanitas Institute, Rozzano, Italy
Filippo De Braud
Medical Oncology and Hematology, IRCCS National Cancer Institute, Milan, Italy
Marina Marchetti
Immunohematology and Transfusion Medicine, Hospital Papa Giovanni XXIII, Bergamo, Italy
Anna Falanga
Immunohematology and Transfusion Medicine, Hospital Papa Giovanni XXIII, Bergamo, Italy
Background The measurement of thrombin generation (TG) potential by the calibrated automated thrombogram (CAT) assay provides a strong contribution in identifying patients at high risk of early disease recurrence (E-DR). However, CAT assay still needs standardization and clinical validation. Objective In this study, we aimed to validate the role of TG for E-DR prediction by means of the fully automated ST Genesia system. Methods A prospective cohort of 522 patients from the HYPERCAN study with newly diagnosed resected high-risk breast cancer was included. Fifty-two healthy women acted as controls. Plasma samples were tested for protein C, free-protein S, and TG by ST Genesia by using the STG-ThromboScreen reagent with and without thrombomodulin (TM). Results In the absence of TM, patients showed significantly higher peak and ETP compared with controls. In the presence of TM, significantly lower inhibition of ETP and Peak were observed in patients compared with controls. E-DR occurred in 28 patients; these patients had significantly higher peak and endogenous thrombin potential (ETP) in the absence of TM compared with disease-free patients. Multivariable analysis identified mastectomy, luminal B HER2-neg, triple negative subtypes, and ETP as independent risk factors for E-DR. These variables were combined to generate a risk assessment score, able to stratify patients in three-risk categories. The E-DR rates were 0, 4.7, and 13.5% in the low-, intermediate-, and high-risk categories (hazard ratio = 8.7; p < 0.05, low vs. high risk). Conclusion Our data validate the ETP parameter with a fully automated standardized system and confirm its significant contribution in identifying high-risk early breast cancer at risk for E-DR during chemotherapy.